TG THERAPEUTICS
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found o... n mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
TG THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
1993-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.tgtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(212)554-4484
Email Addresses:
[email protected]
Total Funding:
205 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Apache
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - TG Therapeutics
Hercules Capital
Hercules Capital investment in Post-IPO Debt - TG Therapeutics
Official Site Inspections
http://www.tgtherapeutics.com Semrush global rank: 2.39 M Semrush visits lastest month: 7.67 K
- Host name: 104.26.15.118
- IP address: 104.26.15.118
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TG Therapeutics"
ABOUT US - TG Therapeutics
We’ve dedicated ourselves to this simple concept and to the study of B-cells and B-cell diseases. To achieve our goal, we search the globe looking for medicines in early research that we believe could become valuable treatment options for …See details»
OVERVIEW - TG Therapeutics
TG Therapeutics is committed to the development of innovative medicines and unique combinations that deliver novel treatments for patients suffering from B-cell malignancies and …See details»
Investor Relations | TG Therapeutics, Inc.
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.See details»
TG Therapeutics Company Profile | Management and Employees …
Www.tgtherapeutics.com . TG Therapeutics Profile and History. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization …See details»
TG Therapeutics - Crunchbase Company Profile
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other …See details»
TG Therapeutics Ranked Number One Fastest-Growing Company …
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of …See details»
TG Therapeutics Inc Company Profile - Overview - GlobalData
Website www.tgtherapeutics.com Telephone 1 212 5544484. No of Employees 173. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange TGTX (NASD) Revenue (2022) …See details»
TG Therapeutics - Overview, News & Similar companies - ZoomInfo
TG Therapeutics contact info: Phone number: (212) 554-4484 Website: www.tgtherapeutics.com What does TG Therapeutics do? TG Therapeutics is a biopharmaceutical company focused …See details»
Guiding Principles - TG Therapeutics
We believe access is essential in ensuring advances are available to patients who are in need of treatment options. At TG we have created a unique approach to decision-making anchored on …See details»
TG Therapeutics Provides Business Update and Reports Second …
Jun 30, 2022 An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call. ABOUT TG THERAPEUTICS …See details»
TG Therapeutics - Craft
Oct 22, 2024 TG Therapeutics has 5 employees at their 1 location and $233.66 m in annual revenue in FY 2023. See insights on TG Therapeutics including office locations, competitors, …See details»
TG Therapeutics - Company Profile - Tracxn
Nov 5, 2024 Developer of treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematological malignancies which include …See details»
Working At TG Therapeutics: Company Overview and Culture
Www.tgtherapeutics.com. Organization Type. Public. CEO. Michael Sean Weiss. Social Media. TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, …See details»
OUR APPROACH - TG Therapeutics
At TG Therapeutics, we have a bold approach to develop novel medicines for patients with B-cell diseases, specifically autoimmune diseases. Our process can be divided into 3 distinct steps: …See details»
Samsung Biologics and TG Therapeutics Expand Collaboration for …
Apr 26, 2021 INCHEON, South Korea and NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and …See details»
Press Releases | TG Therapeutics, Inc.
Nov 1, 2024 Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, …See details»
Trial Information - TG Therapeutics
TG Therapeutics is committed to the development of innovative medicines that deliver novel treatments for patients suffering from B-cell diseases.See details»
OVERVIEW PIPELINE - TG Therapeutics
Dec 28, 2022 The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been …See details»
TG Therapeutics Announces Scheduling of Planned Oncologic …
Mar 10, 2022 This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release …See details»